Back to the atlasDownload source notes

October 6, 2026 — scheduled research update

Home · Latest · Milestones

Focused review of all 32 active condition topics in six groups. The preserved Sleep hub is historical coverage, not a duplicate assignment. Named-program checks and overlap discovery include September 5/6 onward, prioritizing additions since the last focused runs. All broad-topic reviews remain partial: successful-check timestamps are preserved. Source dates, historical baselines, forecasts, registry estimates and rumors remain distinct.

Findings

Coverage by topic

Whole-body MRI

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: whole body MRI screening HERCULES results October 2026 September 2026; whole body MRI September 28 2026 Philip Lacy podcast HERCULES; "whole-body MRI" "October 2026" results screening study

Gaps: Read current topic/state, searched overlap from September 5 (last full success September 12), prioritizing changes missed at October 2 focused check.; Appraised October 1 JGIM systematic review full primary article, HERCULES official study site, and September 28 Andrew Lacy podcast indexed official show notes.; HERCULES live registry API inaccessible; existing April 2025 status/date snapshot not re-verified. No comprehensive international registry, repeated-round outcomes or full podcast/audio sweep.

Informal sources: Revisited September 28 mindbodygreen episode668, Andrew Lacy (Prenuvo CEO) with host Jason Wachob. Original show-note indexing specifies an internally derived 5% radiologically suspected potentially life-saving finding claim, not saved lives or mortality benefit; 200k scans is a commercial experience claim. Full page failed; audio unreviewed. October1 Levels #313 official indexed show notes also located, full page failed. No distinct new rumor selected.

Sources checked:

Galleri and organ-specific cancer screening

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: Galleri FDA approval October 2026 September 2026 colorectal screening results; genomic newborn screening polygenic risk pharmacogenomics trial September October 2026 after:2026-09-25 before:2026-10-07

Gaps: Read topic/current panel and paper events; searched since September5 with October2–6 emphasis. Opened new October5 GRAIL announcement and current news center.; October5 official sponsor source explicitly still says Galleri not FDA-cleared or approved. This is current verification separate from advisory vote.; EDCC/ESMO actual posters and full FDA meeting transcript not appraised. Organ-specific colorectal registry census and SDC2 full-paper gap remain; no complete-topic no-news conclusion.

Informal sources: Searched Galleri FDA timing/Reddit. September24 r/EverythingScience discussion repeats advisory vote and uncertainty; September28 r/ProactiveHealth price discussion is access/anecdote. No original new approval deadline or efficacy rumor verified. Existing approval-timing speculation stays unresolved.

Sources checked:

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: obesity GLP-1 trial October2026 retatrutide eloralintide AMPLIFY; 2026-10-06: NEJMoa2604169 PubMed; 2026-10-06: ClinicalTrials.gov LastUpdatePostDate September5–October6; interventional DRUG, obesity/GLP1; first50; 2026-10-06: Reddit EASD EloraTZP, original 1wu5875 claim and Oct5 1wyga38 repost

Gaps: September5–October6 overlap; prioritize unpublished/recovered September29 TRIUMPH1 and newly registered metabolic trials. First50 recent drug-intervention records inspected; pagination remains. No worldwide safety/access/incretin census or new curve digitization.; Enicepatide NCT06628362 now COMPLETED in October6 record; endpoint timing discrepancy versus sponsor report was not fully reconciled.

Informal sources: Read original u/Hopeful_Candle_9781 September30 thread and Oct5 r/Eloralintide repost; week31 near30%/future approvals remain unsupported/mixed-study claims. No new efficacy leak promoted. Full EASD Q&A/podcasts not reviewed.

Sources checked:

Muscle building and preservation

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28myostatin+OR+bimagrumab+OR+enobosarm+OR+%22muscle+preservation%22+OR+deramiocel%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json

Gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 22 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. Full BELIEVE post-withdrawal tables and new HOPE-3 long-term harms tables were not recovered; original Cantor webcast remains unreviewed.

Informal sources: Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete.

Sources checked:

Longevity and healthspan trials

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: human longevity October2026 rapamycin metformin senolytics trials; 2026-10-06: PEARL24month AgingCell exact paper source-chain follow-up; 2026-10-06: direct NCT07520110/NCT06658093/NCT05835999/NCT07144293/NCT04742777

Gaps: September5–October6 overlap plus older program recovery; direct RESTOR, MAVRIC, everolimus and IPACE-HIV records rechecked. No new material efficacy finding in these focused sources; incomplete broad coverage.; AFAR TAME page fetch failed; funded launch cannot be refreshed. AgelessRx Oct5 updated explainer repeats the pilot and does not provide verified larger-trial initiation; no new efficacy event. Full senolytic/mTOR registry census and original audio incomplete.

Informal sources: Vitaei Apr11 claim revisited and its primary link checked: unrelated2023 cellular-aging paper. October Reddit AMPK items are preclinical and excluded. Full Kaeberlein/Attia/other original podcasts not appraised.

Sources checked:

Localized fat removal and cellulite

Coverage: partial. 0 recorded entries; full-topic successful-check date unchanged.

Searches: CBL-514 RZL-012 tesamorelin cellulite trial October 2026; cellulite randomized trial October 2026 treatment; site:caliwaybiopharma.com/en/news-detail 2026 October; site:theratech.com tesamorelin September October 2026; ClinicalTrials.gov named programs AND LastUpdatePostDate 2026-09-05 to 2026-10-06; broader regional-fat/cellulite discovery 2026-09-25 to 2026-10-06; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: Prior October2 CBL-514 EASD pooled VAT subgroup and September23 first-dose release deduplicated. SUPREME01 remains recruiting320 with July2027 primary/September2027 final estimates; AYP101 completed252, no posted results. Tesamorelin NCT03375788 remains completed51 with old posted results; no new indication asserted. Existing EGRIFTA formulation remains separate from HIV indication.; RZL012 named phase2 records unchanged; no new China NDA filing/readout verified. No new regional-fat or cellulite entrants returned in date-filtered search. Full original EASD tables, SUPREME02 current matched registry, updated global cellulite comparisons, regulator census and rare-harm inventory remain incomplete. Broad EuropePMC discovery failed503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: Targeted Reddit/talk searches found October2–5 CBL514 self-experiment/sourcing threads and tesamorelin/retatrutide anecdotes, excluded from formal-development efficacy. Permalinks searched: https://www.reddit.com/r/Biohacking/comments/1ww4w3j/cbl514/ and https://www.reddit.com/r/BodyHackGuide/comments/1sschiz/does_anyone_have_first_hand_experience_with_cbl514/ . No new attributable formal trial rumor selected; incomplete podcast/full transcript review.

Sources checked:

Broad cardiovascular prevention, lipids and screening

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: lipid lipoprotein cholesterol trial October2026 results; 2026-10-06: NST1024 title PubMed/publisher; 2026-10-06: ClinicalTrials.gov September5–October6 interventional PCSK9/lipoprotein(a)/coronary plaque first50; 2026-10-06: October2026 lipoprotein podcasts; Curbsiders541

Gaps: September5–October6 recent registry discovery; first50 records plus direct HEART3/DR10624 statuses and sponsor discovery. Broad search is nonspecific and paginated; no complete Lp(a)/ApoB/prevention-screening census.; COR2003/COR1004 NCT07858019 is a newly registered phase1 lead; target/mechanism not independently verified, so no precise target claim. NST1024 September29 journal publication found, but full primary effect/safety details unavailable; remains coverage gap. COMPETE SWITCH CV original HR orientation/counts remain unresolved.

Informal sources: Curbsiders Oct5 lipid-guideline episode discovered; page fetch failed and audio not appraised. Recent commentary mainly repeats HORIZON failure. No original new outcome leak verified.

Sources checked:

Alzheimer's screening and therapies

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: AlzheimertherapybiomarkerbloodtestclinicaltrialOctober2026 after:2026-10-01 before:2026-10-07; site:reddit.com "Alzheimer" "October" "2026" trialobicetrapib; site:clinicaltrials.gov "SAR448851"; "SAR448851" NCT phase2 2026

Gaps: Read full topic/state. Located and opened October 6 UMIN STRIDE-PAD diagnostic-pathway registration; opened original Attia/Davidson public episode page.; SAR448851 program located via official Canada/EMA leads but live CT.gov shell/API unusable; not promoted as new October initiation based on an aggregator's September 28 date.; Full antibody labels/ARIA/assay recalls and prevention registries not refreshed. Original paid Attia transcript unreviewed; no cognitive-prevention benefit from SPINOZA recruitment.

Informal sources: Reopened Attia/Davidson public notes; existing Alzheimer-prevention hypothesis remains unconfirmed despite official SPINOZA recruitment. October 5 Reddit high-dose psilocybin case-report claim surfaced but original page failed; no formal new therapy claim promoted. Full paid transcript/Reddit census incomplete.

Sources checked:

Coverage: partial. 0 recorded entries; full-topic successful-check date unchanged.

Searches: psychedelic depression anxiety psilocybin trial October2026 after:2026-10-01 before:2026-10-07; site:ir.compasspathways.com "2026" "October"; site:investor.ghres.com "October" "2026"; site:ir.helus.com "October" "2026" clinical; site:ir.definiumtx.com "October" "2026" clinical; "Adverse Health Outcomes of Psilocybin,LSD,MDMA,Ibogaine,and5-MeO-DMT"

Gaps: Read current topic/state; October 1 Helus legal-name and October 5 Compass office news add no clinical results or approval. Opened FDA hearing page and actual September 29 JAMA public-health survey.; FDA comment deadline October 5 at 23:59 ET elapsed; no new policy/product decision verified. Full hearing recording/transcript and HLP003 posters remain unappraised.; Safety survey appraised as context, not regulated-trial results: mixed/unsupervised use cannot quantify clinical-trial risks. Broad registry/sponsor-call coverage incomplete; no full-topic no-news claim.

Informal sources: October 2 r/shroomstocks safety-paper thread traced to September 29 JAMA letter, not an October 2 trial. October 3 HLP003/HLP004 prediction thread is investor opinion without new original inside information. October 5 Alzheimer psilocybin case-report claim located but original post failed; excluded from formal therapy findings. Existing Resilient MDMA refiling remains unverified for FDA acceptance. Full podcast/transcript review incomplete.

Sources checked:

Mental-health treatments, SSRIs and newer antidepressants

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: antidepressant SSRI depression PTSD OCD clinical trial October2026 after:2026-10-01 before:2026-10-07; "SSRI" "October2026" trialresults; "antidepressant" "October5,2026" trial; "Low-Intensity Focused Ultrasound of the Amygdala in Depression and Anxiety"; site:reddit.com depression antidepressant newtrial fasedienol liafensine October2026; fluoxetine children "2026" "Naudet" "meta" trial reanalysis; "cesm.70108" "-0.26" "-0.23"

Gaps: Read current topic/state; appraised October 1 pediatric fluoxetine reanalysis full primary paper, September 20 amygdala FUS primary preprint abstract and current informal leads.; FUS is newly recovered recent evidence from the overlap, not an October 6 trial; full medRxiv/PMC pages blocked. SSRIs remain distinct from neuromodulation and ketamine.; All OCD/PTSD/addiction/bipolar registries and labels not refreshed. Perospirone October 2 commentary traced to a 2025 paper, not new news; psychotherapy NCT07857629 lead not promoted without primary appraisal.

Informal sources: October 4 original r/science fluoxetine post traced to the actual October 1 primary reanalysis; a claim that the 2006 trial created pediatric approval would be unsupported. October 5 Psychiatry emotional-blunting discussion consists of anecdotes/hypotheses, not a new controlled outcome. October 5 clinician glutamatergic video revisits the old Auvelity program; no distinct new development rumor selected. Full talk/podcast coverage incomplete.

Sources checked:

Bone health, joint preservation and cartilage repair

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28osteoporosis+OR+%22cartilage+repair%22+OR+lorecivivint+OR+%22TG-C%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json

Gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 91 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. ACTiVION-I October readout not verified; full osteoporosis cell-therapy paper and EB613 initiation remain gaps. Lorecivivint EMA forecast now resolved by a retrieved sponsor release.

Informal sources: Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete.

Sources checked:

Liver health and noninvasive assessment

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: MASH trial October2026 lanifibranor efruxifermin pegozafermin; 2026-10-06: ClinicalTrials.gov September5–October6 interventional MASH/NASH first50; 2026-10-06: Wegovy MASH SeptemberCHMP EMA outcome; EPAR current SmPC; 2026-10-06: Reddit OctoberMASH and saved September18 CHMP original

Gaps: September5–October6 overlap; first50 recent MASH/NASH registry records and direct new ALNCIDEB/AROINHBE protocols read. Efruxifermin/pegozafermin/survodutide ongoing records are not new results. Full cirrhosis/noninvasive test census remains incomplete.; Wegovy EPAR and September21 product information checked: no steatohepatitis indication located. This does not determine the September CHMP variation outcome or infer rejection. NATiV3 Q4 topline remains forecast, no result verified.

Informal sources: Original September18 u/kiyomoris CHMP-omission inference revisited; current SmPC does not resolve the actual procedure disposition. No approval/rejection inferred. Original full EASL podcasts/talk audio not appraised.

Sources checked:

Cancer treatment, vaccines and recurrence prevention

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: cancer vaccine clinical trial oncology results October 2026 after:2026-10-01 before:2026-10-07; site:reddit.com cancer vaccine October 2026 trial results REGAL IDOV2 interpath after:2026-09-25 before:2026-10-07; site:fda.gov drugs oncology "October" "2026" approves; cancer phase3 results September29 October5 2026 trial immunotherapy oncology; "IDOV2" September October2026 clinical trial; "cancer vaccine" "October" "2026" "phase" trial; site:ir.sellaslifesciences.com "August11,2026" "REGAL"

Gaps: Read current broad-oncology/vaccine topic/state, deduplicated evERA/approvals/INTerpath schedule. Search focusedOctober2–6 plus September5 overlap.; Appraised September24 IMpassion050 final primary abstract and original SELLASAugust11 release; newOctober2 Reddit REGAL timing inference original opened.; Full IMpassion safety appendix inaccessible; broad cellular/radiopharmaceutical/vaccine registry sweep incomplete. ASTEROIDSeptember30 accepted manuscript located but fullpaper failed; IDOV2 literal source remained unmatched. All are gaps, not no news.

Informal sources: Original October2 Run4theRoses2 REGAL event80 any-day-now post opened; it is extrapolation from aggregate death counts with conspicuous investment promotion, not inside information. Existing September27 REGAL outcome guesses do not independently corroborate it. Source date recovered from indexed original; sponsorAugust11 describes event-triggered analysis with no calendar date. Can record a new clearly labeled speculation item, but do not promote efficacy or approval expectations.

Sources checked:

Autoimmune disease and immune reset

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28%22CAR+T%22+OR+%22immune+reset%22+OR+fenebrutinib+OR+%22Treg%22%29+AND+%28lupus+OR+myositis+OR+%22multiple+sclerosis%22+OR+%22rheumatoid+arthritis%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json

Gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 28 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. No new restart announcement verified for paused rapcabtagene/zolecabtagene; unchanged/pre-pause registry records cannot prove restart. C-CAR168 remains not yet recruiting. Complete long-term CAR-T safety and transcript review incomplete.

Informal sources: Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete.

Sources checked:

Non-opioid pain treatments

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28suzetrigine+OR+%22VX-993%22+OR+onzotrigine+OR+%22LTG321%22+OR+%22non-opioid%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json

Gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 40 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. Full LTG321/onzotrigine regulatory correspondence, VX-993 detail and all pain-mechanism literature not appraised.

Informal sources: Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete.

Sources checked:

Kidney preservation and earlier detection

Coverage: partial. 5 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: kidney trial October2026 results -kidney cancer; 2026-10-06: REMODEL s41591-026-04674-2 primary paper; 2026-10-06: ClinicalTrials.gov September5–October6 CKD/IgAN interventional first50; 2026-10-06: Reddit kidney new trial October2026; SeaStar ASN original release; kidney podcasts

Gaps: September5–October6 overlap discovery; primary REMODEL paper including null primary outcomes and safety read. First50 recent CKD/IgAN records inspected; pagination/new disease-specific therapies and early detection census incomplete.; Sefaxersen numerical interim/safety disclosure, ORIGIN3 full final safety, EASi-KIDNEY final quantitative analysis remain gaps. New SAVE poster scheduled but not yet reviewed; FDA HDE route and exact indication independently verified; full historical benefit/safety appraisal remains incomplete.

Informal sources: Oct2 r/SeaStarMedical post repeats sponsor ASN announcement; original sponsor confirms date, not a numerical result. Broader kidney podcast/audio and patient anecdotes not comprehensively appraised.

Sources checked:

Hearing and vision preservation/restoration

Coverage: partial. 3 recorded entries; full-topic successful-check date unchanged.

Searches: PRIMA36monthresultsOctober3 2026 EURETINASciencevision; MCO-010geographicatrophyOctober4 2026 EURETINAresults; OPGxBEST1EURETINAOctober4 2026 clinicaldata; "Science" "PRIMA" "October5,2026"; "PRIMA" "36" "29" "2026" Science; "MCO-010" "October" "2026" "atrophy"; "MCO-010" "EURETINA" "2026"; "MCO-010" geographicatrophy "NCT" 2026 randomized; site:reddit.com "hearing" "AC102" "October" "2026"

Gaps: Read topic/state; followed elapsed EURETINA October 3/4 catalysts. Actual new PRIMA 36-month numerical release opened from Science's Business Wire/AOL syndication; original Business Wire unavailable.; October 1 Japan MOGENRY priority-review and October 6 AAO schedule opened on sponsor site. Inherited RP/IRDs kept separate from acquired AMD/GA.; Actual BEST1 EURETINA PDF now listed on sponsor index, but download returned 403 and local network unavailable. No new numbers inferred. MCO-010 October 4 GA abstract/slides not retrieved; registry unmatched. ARMD observer October 4 notes describe three Stargardt patients, not a verified GA result.; PST-611 actual October 2 presentation, DAYBREAK/BRUNELLO tables and regulator/label/acquired-hearing inventory remain unappraised. AC102 purported-email thread revisited; no official phase 3/tinnitus confirmation; live API failed.

Informal sources: Original ferttt2 August 29 AC102 purported-email thread opened; conditional 2027 phase 3/tinnitus plans remain unconfirmed, with no proven chronic-tinnitus benefit or authenticated email. PRIMA durability news traces to an actual sponsor release. ARMD observer Stargardt summary does not verify new GA efficacy. Wider podcast/talk sweep incomplete.

Sources checked:

Hair loss, restoration and graying

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: PP405 ABS-201 clascoterone VDPHL01 October 2026 hair trial; PP405 ABS-201 KX-826 GT20029 BQ-002 October 2026; bempikibart alopecia areata EADV October 2026 upadacitinib; site:reddit.com greyhairreversal BQ002 BioCopper October 2026; ClinicalTrials.gov alopecia/hair-graying updated September25–October6 plus named-program September5–October6 overlap; milk-derived MEV-miRNA gel October2026 randomized trial methods; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: PP405 Oct2 recruiting milestone already captured October3, not re-alerted. HEADLINE ABS201 unchanged recruiting; phase1/2 metadata remains distinct from phase1 safety evidence. BioCopper remains not yet recruiting88, November2026 start and July2027 completion estimates. Bempikibart and Olumiant September events deduplicated.; New-to-watch Olistic NCT07484061 (March19 registration, updatedOct6, recruiting40; GLP1/GIP users, six-month randomized supplement/placebo) is a baseline lead, not demonstrated treatment. Full current Cosmo/Kintor/Veradermics and AA conference/regulator refresh remains incomplete.; October1 milk-exosome/miRNA plus iSFRP1 gel RCT lead: indexed original describes40 randomized,39 completed,12weeks, short-term trichoscopic gains. Original HTML/PDF/XML returned403/429; full tables, adjusted effect intervals, funding and harms could not be appraised. Methods also call randomized intervention an unregistered observational investigation. Do not promote as a settled efficacy finding. URL attempted: https://www.mdpi.com/2079-9284/13/5/261 . EuropePMC503 prevented broad paper census.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: BQ002 saved rumor re-opened with original Reddit/BioQ: candidate exists, but matched human trial and2027 start remain unconfirmed; no new status alert. PP405 saved September claim remains only partly corroborated by official Oct2 recruiting status/September21 actual start; earlier email/individual dosing unverified. Oct4 r/tressless thread (https://www.reddit.com/r/tressless/comments/1wxeah3/its_q3_2026_where_are_we_at_with_the_novel/) contains speculative PP405-is-dead assertions tied to alleged chemistry and graymarket self-experiment, without an official discontinuation source; current trial remains recruiting. Original thread open failed, indexed text only; no rumor selected. Clascoterone launch rumor not fully reappraised.

Sources checked:

Skin aging, laxity and regeneration

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: KB304 skin rejuvenation clinical trial October2026 radiofrequency; skin rejuvenation laxity randomized October2026 clinical trial; skin rejuvenation microneedling October2026 FDA safety; skin rejuvenation podcast October2026 KB304 trial; ClinicalTrials.gov skin-aging/rejuvenation/laxity/wrinkles updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: KB304 remains active not recruiting, stale estimated July2025 completion; no new Phase2 start verified. RF-microneedling FDA communication still datedOctober15,2025, ongoing evaluation; not a new2026 alert. Existing polynucleotide and biosome reports deduplicated.; L’Oreal R0090948A NCT07853027 firstpostedOct1, planned13, not yet recruiting; mitochondria/UV stress markers not visible durable rejuvenation. Lower-priority registry lead, no news efficacy. Broad paper search failed503; new Sept22 multimodal RF RCT PMID42766316 abstract not fully fetched/appraised; global device clearance and procedure comparative/rare-safety review incomplete.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: October2 unPAUSED MaryClaireHaver skin-treatment episode show-description/timestamps found (https://podfollow.com/unpaused-with-dr-mary-claire-haver/episode/fe943932b44edaffd4043acbd9653c7879ccb100/view), but full original open failed and audio/transcript not appraised; no specific trial milestone verified. Saved Sept29 Lufkin/Durairaj rapalog/GLP1-face episode direct Buzzsprout fetch failed; no new clinical claim adopted.

Sources checked:

Scar prevention, treatment and stretch marks

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: SNT9465 verteporfin stretchmarks scar October2026 clinical trial; scar keloid stretchmark verteporfin October2026 trial; site:reddit.com verteporfin SCARFREE October2026 trial; ClinicalTrials.gov scar/keloid/striae updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: October1 Syntara expansion/tolerability/null-clinical-signal already recorded; no new efficacy. Geneva verteporfin remains not yet recruiting with stale2026 estimates; siSPARC unknown/staleJune2024. SCARFREE primary update corrects misleading mirror timing.; New registry disclosure ON101 contains structured/narrative inconsistencies. Other low-priority new records: NCT07849010 skinclosure25 recruiting (Sep30); NCT07850557 pressure in burn amputees12 not yet recruiting (Sep30). No results. Full stretchmark comparative trials, matched Syntara IDs and rare harms remain incomplete; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: Targeted original saved Aug26 r/verteporfin thread (https://www.reddit.com/r/verteporfin/comments/1vypnsk/verteporfin_status_upcoming_trials_and/) re-found: its assertions of ongoing formal trials are not verified by stale NYR Geneva/SCARFREE records. Sept23 off-label-testing comment in https://www.reddit.com/r/ReverseRhinoplasty/comments/1uf4elm/healing_wounds_with_reduced_scarring_verteporfin/ describes personal physician-assisted testing, not a new regulated-trial result. No new formal-program rumor selected; full investor recordings not reviewed.

Sources checked:

Facial volume restoration and contour

Coverage: partial. 3 recorded entries; full-topic successful-check date unchanged.

Searches: facial filler fatgraft trial October2026 volume restoration FDA; facialvolume filler Radiesse October2026 trial approval; site:reddit.com facialcontours filler September2026 Adipeau; ClinicalTrials.gov facial-volume/filler/fatgraft updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: Macrofat NCT07805889 unchanged recruiting400, Dec10,2026/Mar1,2027 estimates; no results. GLP1-Radiesse NCT07419854 recruiting, no results. New Facetem/Radiesse registries and HArmonyCa completion appraised.; RHA4 active-comparator full paper newly accessed is August2026 historical context, not October news:201 total,173 primary PP; at8weeks mean change-1.3 both arms, CI difference[-0.22,0.25], prespecified0.5 noninferiority margin. Sponsored and mostly women; no superiority/rare-harm inference. FDA exact new product/indication PMA census and global rare/delayed filler safety incomplete; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: Saved Sept30/Oct1 Adipeau brand-contour post (https://www.reddit.com/r/u_Adipeau/comments/1wubdvg/restoring_facial_contours_without_filler_where/) remains promotion rather than a new controlled outcome; original fetch failed. Saved Lufkin/KayDurairaj episode (https://www.buzzsprout.com/1848150/episodes/19344405-ozempic-face-why-weight-loss-can-make-you-look-older-kay-durairaj-md?t=0) failed direct open; no full transcript/timestamp claim adopted. October5 physician AMA located but not fully appraised; anecdotal technique comments not treated as trial results.

Sources checked:

Pigmentation and uneven skin tone

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: vitiligo povorcitinib ruxolitinib EADV October2026 melasma trial; vitiligo melasma treatment EADV October2026; FXS5626 vitiligo; melasma post-inflammatory randomized September2026; ClinicalTrials.gov melasma/vitiligo/hyperpigmentation updatedSeptember25–October6; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: VitiUp Oct1 extension/UVB findings already captured. STOP-V1/V2 original APIs unchanged active not recruiting with no posted results,467/450 actual; DelVito unchanged. FXS5626 registration newly recovered.; Full Incyte EADV P2467/P1780/P2463 actual posters still not retrieved; do not mark scheduled presentations as reviewed results. Broad melasma/PIH/solar-lentigine original-paper census, KT939 protocol and current regulator/action sweep incomplete; EuropePMC503. Fosun Sept8 primary release indexed text found but direct open failed; FXS registration itself was actually downloaded.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: Targeted Reddit/postcast searches found Oct3 upadacitinib use/access anecdotes (https://www.reddit.com/r/Vitiligo/comments/1ww9d49/upadacitinib_update/) and older vitiligo pipeline recaps; no new attributable trial/approval forecast selected. Personal OTC/Rx overseas access anecdotes do not establish U.S. approval. Full original audio not reviewed.

Sources checked:

Acne and rosacea

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: denifanstat AURORA acne rosacea October2026 trial; site:sagimetbiosciences.gcs-web.com AURORA denifanstat October2026; acne rosacea clinicaltrial October2026 remibrutinib; rosacea remibrutinib trial2026; ClinicalTrials.gov acne/rosacea updatedSeptember25–October6; denifanstat AND acne all records; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: AURORA October screening remains sponsor forecast; current denifanstat+acne registry query yields only two Chinese completed studies, no matched U.S. AURORA study. Sept30 extension already captured; Oct1 financing is not clinical efficacy/initiation. Existing RF acne/rosacea redness records unchanged; SP0268 full current API not refreshed in this batch.; Remibrutinib PPR baseline recovered with original registry and HealthCanada protocol. New NCT07854418 Winona postacne-erythema retrospective study80 completed has internally differing narrative/structured schedules and no results; cosmetic care lead not promoted. Full acne/rosacea antibiotic/resistance/device/ocular/redness coverage and EADV data/safety-regulator census incomplete; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: Targeted Reddit searches yielded individual rosacea treatment stories and Oct4 UK Finacea shortage complaints (https://www.reddit.com/r/Rosacea/comments/1wxaxy3/finacea_out_of_stock_everywhere_uk/), without verified manufacturer/supply statement. Do not extrapolate to U.S. shortage. Sagimet Sept30 webcast replay/supporting slides are listed on original events page; Q&A/audio not appraised. No new rumor selected.

Sources checked:

Dental alignment, regeneration and repair

Coverage: partial. 3 recorded entries; full-topic successful-check date unchanged.

Searches: Toregem TRG035 October2026 dental aligners randomized trial toothregeneration; dental orthodontic enamel periodontal randomized trial October2026; P11-4 Bonchev45 randomized trial enamel2026; Bonchev NCT06749977 publication; ClinicalTrials.gov alignment/repair/regeneration updatedSeptember25–October6; Root-discovered NCT07859358 original primary API retrieval; EuropePMC TITLE_ABS discovery FIRST_PDATE:[2026-09-05 TO 2026-10-06] (HTTP503 coverage gap)

Gaps: September24 printed-aligner paper already captured. NCT07496892 remains NYR with stale March27 record and elapsed September completion estimates; no completion presumed. OrthoPulse records remain completed/noresults or unknown/stale. Toregem Oct2 global startup support and Oct6 BioJapan booth announcements add no first-dosing or efficacy verification; phaseIIa August17 trial-notification remains separate from approval.; New P114 official conference abstract and matching original record appraised. Additional new orthodontic registrations disclose historical completed bracket/laser/ultrasound studies without results; no efficacy selected. Full printed-aligner/root/gum/retention papers, Japanese jRCT PhaseIIa primary record and broad repair/regeneration census remain unappraised; EuropePMC503.; Focused source checks completed, but full-topic coverage incomplete; preserve original last_successful_check_utc. Recent registry discovery covered September25–October6; named-program checks and web discovery included the September5 overlap. This is not an exhaustive worldwide registry or literature review.

Informal sources: Saved toothregrowth Reddit repost (https://www.reddit.com/r/Biohackers/comments/1wq1adh/910_dentists_probably_wont_recommend_this/) still repeats earlier2030 forecasts and extrapolation to adult missing teeth. Current sponsor business announcements do not confirm that forecast. Targeted informal/podcast search found no new attributable formal milestone; full audio and original-comment census incomplete.

Sources checked:

Allergy and airway disease

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28asthma+OR+COPD+OR+%22food+allergy%22+OR+%22chronic+sinusitis%22%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json

Gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 120 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. No fuller rademikibart absolute event/safety table or verified VIASKIN filing-acceptance target recovered. Sinus-disease and guideline survey incomplete.

Informal sources: Focused Reddit and named-program searches; anecdotes/reposts were not treated as trial evidence. Broader podcast/talk coverage remains incomplete.

Sources checked:

Infectious-disease prevention and treatment

Coverage: partial. 3 recorded entries; full-topic successful-check date unchanged.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28antibiotic+OR+bacteriophage+OR+vaccine+OR+antiviral%29+AND+%28%22PHASE2%22+OR+%22PHASE3%22%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-06%5D&pageSize=100&format=json

Gaps: Named registry refresh and overlap discovery completed; comprehensive literature, all regulatory files and informal transcripts remain incomplete. Full-topic successful-check date is preserved. Official registry discovery returned 282 records, from all returned pages; appraisal focused on named programs and new first postings. Incidental matches were excluded. VYD2311 efficacy remains blinded/pending; AP-SA02 phase 3 actual initiation and REPhRAME formal protocol not verified. Full new-antibiotic/access census incomplete.

Informal sources: Reddit VAX-31 threads mostly repeat the release and infer approval/market timing; no separate rumor promoted. Saved VYD2311 October safety/titer forecast remains separate from blinded efficacy. Phage anecdotes are not controlled evidence; broader podcast/talk review incomplete.

Sources checked:

Genetic screening and risk prediction

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: genomic screening polygenic risk pharmacogenomics newborn embryo October 2026 clinical trial; genetic screening embryo polygenic October 2026 trial Nucleus after:2026-09-25 before:2026-10-07; "genetic" "September 2026" "October 2026" "clinical utility" newborn polygenic trial; site:reddit.com genetic screening embryo polygenic Nucleus October 2026; site:reddit.com Nucleus Vitruvian 14 IQ September October 2026

Gaps: Read current genetics/PGT-P notes and state. October5 BeSolveRD primary full paper appraised. Reopened Nucleus official Labs and newly found original September whitepaper.; Recovered direct social permalink through existing Reddit post; X403, original post not independently verified. Whitepaper closes important model-method and ancestry gaps without establishing observed offspring benefit.; Live Nucleus NCT07841769 and T1D NCT07802496 APIs inaccessible; elapsed estimated start not verified. Full newborn/carrier/cascade/PGx inventory incomplete; whitepaper is recovered baseline, not newOctober6 model launch.

Informal sources: Original September27 Reddit reproducing Kian Sadeghi/Nucleus claim revisited; direct X permalink recovered but403. Sponsor whitepaper gives14.3-point modeled highest-lowest spread with10 European-ancestry embryos, top-vs-average gain half that, not generic14point observed gain. Existing stable key nucleus_vitruvian_2026-09-27_IQ_claim remains unconfirmed as worded; sources/methods clarified, no repeated alert or offspring benefit claim.

Sources checked:

Insomnia

Coverage: partial. 3 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: daridorexant daytime-function study October2026; direct named-drug registry search (30latest); 2026-10-06: insomnia digital CBT trial SeptemberOctober2026, PubMed42623797; 2026-10-06: Reddit DARIDREAM/insomnia trial leads

Gaps: Pending condition baseline partially refreshed across preceding90days, new DARI-DREAM protocol, COMISA and older digital pilot. Existing ten-drug baseline and digital meta-analysis retained; no completed comprehensive baseline.; Full DARI-DREAM protocol/daytime-label intent and actual dosing remain unverified; full digital-pilot text blocked, PubMed XML read. Device/new-drug/digital worldwide census and original podcast sweep incomplete.

Informal sources: No noteworthy attributable DARI-DREAM leak found; personal medication/CBTi discussion is not trial efficacy. Podcast recordings and all trial-participant threads incomplete.

Sources checked:

Obstructive sleep apnea

Coverage: partial. 1 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: sleep apnea AD109 October2026 podcast/newresults; 2026-10-06: TRIUMPH1 primary PubMed, NCT05813275 postedresults, NCT07225686 protocol; 2026-10-06: OSA oral-appliance podcast October2 and recent Reddit apnea

Gaps: Inherited October3 diagnostic/treatment baseline retained; TRIUMPH1 publication cross-linked, AD109 primary results record and MARITIME OSA protocol read. Broad device/diagnostic/new-drug baseline still partial.; Full AD109/TRIUMPH1 supplements and comparative safety/durability not independently reappraised. PAP/oral-appliance/surgical stimulation/validated wearable discovery census incomplete.

Informal sources: AADSM OpenAirWaves Oct2 oral-appliance/OMT episode discovered, page fetch failed and full audio not reviewed. Personal device experiences excluded as efficacy. No verified new AD109 rumor.

Sources checked:

Narcolepsy & excessive sleepiness

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: narcolepsy orexin agonist SeptemberOctober2026 Centessa ORX750 TAK360; registry query30latest; 2026-10-06: cleminorexton SAPPHIRE direct NCT07598708; 2026-10-06: oveporexton DEA FederalRegister scheduling and official product page; 2026-10-06: original Orzeyful waiting room RedditSep24

Gaps: Pending condition baseline partially expanded with cleminorexton aliases/SAPPHIRE/CRYSTAL1, TAK360 and direct alixorexton/Vibrance3 status. Sources cover earlier90days and older pivotal context selectively.; Orzeyful sponsor page still says expected byNovember pendingDEA; final official DEA action not established. Established oxybate/stimulant/solriamfetol/pitolisant full label and new-program safety census incomplete. Centessa annual-report PDF exceeded webtool size; no numerical new efficacy/safety claims drawn from it.

Informal sources: Sep24 r/Narcolepsy thread by Dobby_1235 repeats November forecast; a Requiredmetrics comment describes local TAK360 trial eligibility, not evidence of a new milestone. Exact comment times are not reliable from relative rendered labels; source original indexedSep24. Anecdotes are not efficacy or safety rates. Full conference/podcast recordings incomplete.

Sources checked:

Circadian rhythm disorders

Coverage: partial. 2 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: circadian shift-work SeptemberOctober2026 clinicaltrials tasimelteon; 2026-10-06: tasimelteon July20 hearing2026 FDA docket query; 2026-10-06: circadian-condition interventional registry30latest; direct NCT04652882/NCT06568367; 2026-10-06: RedditDSPD/N24 SeptemberOctober2026; seasonal Hetlioz experience

Gaps: Pending condition baseline partially expanded by DSWPD tasimelteon and SUSTAIN shift-work trials; latest30 circadian registry records screened with irrelevant mechanistic/consumer studies excluded.; Tasimelteon jet-lag prehearing July20 outcome/newdate not verified; FDA hearingnotice only. Timed light/dark/melatonin disorder-specific trials and pediatric/shiftwork broad baseline remain incomplete. SUSTAIN sponsor readout timing not freshly retrieved; registry completion is only an estimate.

Informal sources: Sep11 r/N24 seasonal Hetlioz personal-experience lead surfaced, directpage fetch failed; no clinical development rumor promoted. No original circadian podcast/talk recording appraised.

Sources checked:

Restless legs syndrome

Coverage: partial. 3 recorded entries; full-topic successful-check date unchanged.

Searches: 2026-10-06: RLS SeptemberOctober2026 trial iron perampanel Nidra; 2026-10-06: RLS interventional registry30latest; NCT07822607/NCT07675109; 2026-10-06: September16 venousRFA original abstract; AASM2025guideline; 2026-10-06: RedditRestlessLegs Oct3Nidra and trial publication anecdotes

Gaps: Pending condition baseline partially expanded beyond Nidra with IViron randomized timing trial, XD-TOMAC and controlled/observational discovery. Latest30RLS interventional records screened; important older drug/iron trials, guidance and safety still need full reconciliation.; September16 venous-ablation full methods/harms remain inaccessible. AASM2025guideline indexed primary text reviewed, directPMC returned recaptcha; full guideline/label baseline not complete. ConferenceSOS2026fulltalks and original podcasts not appraised.

Informal sources: Read Oct3 original Only-The-ShadowKnows thread: mixed personal drug/device experiences and anonymous comments predicting Stanford-study publication; no attributable source/date for a new formal readout, so no efficacy/launch rumor promoted. OriginalSOS2026talks/audio not reviewed.

Sources checked:

Homepage review and publication

The October 3 EloraTZP feature remains useful: randomized active-comparator evidence with matching-arm tolerability. It is retained rather than rotating after three days. No historical plotted values, curves or research dates are changed by export. Only affected histories/frontier/reference details are refreshed. This background run skips user-facing browser preview; validators and native deployment status provide separate checks. The website publication receipt is kept in state.json after successful publication.